Drug Profile
Research programme: long-acting beta-agonists - Sepracor
Alternative Names: LABAs - SepracorLatest Information Update: 28 Oct 2010
Price :
$50
*
At a glance
- Originator Sepracor
- Class
- Mechanism of Action Beta-adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 13 Oct 2010 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 13 Oct 2010 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (unspecified route)
- 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma